DGAP-News: SphingoTec to Present at the LifeSci Partners' Summer Symposium

Primary tabs

Please click the following link to register: https://lifesci.events/SummerSymposium

Information
Retrieved on: 
Friday, July 31, 2020 - 12:10pm
Geotags: 
Content
Key Points: 
  • Please click the following link to register: https://lifesci.events/SummerSymposium
    SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies.
  • SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression.
  • IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.
  • For more information please visit our website: https://sphingotec.com/



DGAP-News: SphingoTec GmbH

/ Key word(s): Corporate Action/Conference


SphingoTec to Present at the LifeSci Partners' Summer Symposium

31.07.2020 / 12:30

The issuer is solely responsible for the content of this announcement.


Hennigsdorf/Berlin, Germany - July 31, 2020 - Diagnostics company SphingoTec GmbH ("SphingoTec") today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. 


SphingoTec develops and markets in-vitro diagnostic tests for novel and proprietary biomarkers in diagnostically underserved acute and critical care conditions to improve patient outcomes. The company makes its assays for real-time assessment of kidney function, endothelial function and cardiac depression available on its fully integrated Nexus IB10 point-of-care platform.


Presentation Details:

Date:        August 4, 2020

Time:        3:30 p.m. CEST


Please click the following link to register: https://lifesci.events/SummerSymposium


About SphingoTec

SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care. 


For more information please visit our website: https://sphingotec.com/

Contact:
SphingoTec GmbH

Ferdinand von Humboldt

CFO 

+ 49 330 220 56 50

investors@sphingotec.com


LifeSci Advisors, LLC 

Guillaume van Renterghem

Managing Director

+33 (0)6 69 99 37 83

gvanrenterghem@lifesciadvisors.com

 




31.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1107587  31.07.2020 

fncls.ssp?fn=show_t_gif&application_id=1107587&application_name=news&site_id=jotup